This acquired resistance to alkylating chemotherapy secondary to MMR MSH6 gene mutation was rescued by downstream peroxisome proliferator-activated receptor (PPAR) inhibition of DNA repair—a targeted therapy for TMZ-resistant recurrent glioblastoma [79]. The gene discussed is MSH6; the disease is glioblastoma.